# AtxA2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- AtxA2 is a master transcriptional regulator in *Bacillus anthracis* and related species, essential for orchestrating the expression of anthrax toxin genes (protective antigen, lethal factor, edema factor) and capsule biosynthesis operons, thereby driving pathogenesis.
- The gene's localization varies: it resides on the pXO1 virulence plasmid in *B. anthracis* but is found chromosomally or on plasmids in some *B. cereus* strains, influencing regulatory dynamics and potential for horizontal gene transfer.
- AtxA2 activity is tightly regulated by environmental signals (e.g., CO₂, temperature) through a cascade involving the AtxS/AtxR two-component system and post-translational modifications, including phosphorylation at histidine and aspartate residues, which is critical for DNA binding and transcriptional activation.
- Naturally occurring and clinically significant mutations in *atxA2*, such as H379A (avirulent) and D482G (hypovirulent), directly impact toxin production and are valuable markers for distinguishing virulent from avirulent *Bacillus* isolates, aiding in diagnostics and prognosis.
- AtxA2 serves as a promising anti-virulence therapeutic target; inhibition of its phosphorylation or DNA-binding activity, or targeting its downstream effector toxins (e.g., with monoclonal antibodies like Raxibacumab), represents a strategy to attenuate *Bacillus* infections.

---

## Executive Summary & Key Metadata

AtxA2 is a transcriptional regulator first characterized in the context of bacterial pathogenesis, specifically within the genus *Bacillus*. The gene product functions as a master virulence regulator, orchestrating the expression of anthrax toxin genes and capsule biosynthesis operons. Beyond its canonical role in *Bacillus anthracis*, AtxA2 orthologs and paralogs have been identified across the *Bacillus cereus* sensu lato group, where they modulate host-pathogen interactions, metal ion homeostasis, and metabolic adaptation. This reference manual provides a comprehensive analysis of the AtxA2 gene, encompassing its genomic architecture, three-dimensional protein structure, signal transduction mechanisms, clinical relevance, and pharmacogenomic implications.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | AtxA2 |
| **UniProt Accession** | E8RUP9 |
| **Representative PDB ID** | True (homology model available; experimental structure pending) |
| **Chromosomal Locus** | pXO1 virulence plasmid (in *B. anthracis*); chromosomal in some *B. cereus* strains |
| **Primary Molecular Function** | Transcriptional activator; regulates toxin gene expression, capsule synthesis, and metabolic genes |
| **Disease & Pathology Associations** | Anthrax pathogenesis; hemolytic disease in *B. cereus*; potential biomarker for *Bacillus* sepsis |

The AtxA2 protein is a 55–60 kDa polypeptide that belongs to the AtxA family of transcriptional regulators, characterized by an N-terminal DNA-binding domain and a C-terminal phosphotransferase acceptor domain. The protein is phosphorylated on multiple histidine and aspartate residues, a post-translational modification that is essential for its transcriptional activity. AtxA2 operates within a complex regulatory network that integrates environmental signals—including carbon dioxide concentration, temperature, and host immune factors—to coordinate the temporal expression of virulence determinants.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Plasmid Localization

In *Bacillus anthracis* strain Ames, the *atxA2* gene is located on the pXO1 virulence plasmid (GenBank accession: NC_007322). The gene spans approximately 1,500 base pairs, with coordinates ranging from 143,200 to 144,700 on the pXO1 replicon. The pXO1 plasmid is a 181.6-kb circular DNA molecule that also harbors the anthrax toxin genes *pagA* (protective antigen), *lef* (lethal factor), and *cya* (edema factor). The physical proximity of *atxA2* to these toxin genes is not coincidental; the plasmid architecture has evolved to facilitate coordinated regulation of virulence factors.

In contrast, certain strains of *Bacillus cereus*—particularly those associated with severe extraintestinal infections—carry *atxA2* on the bacterial chromosome. For instance, *B. cereus* strain G9241, which was isolated from a fatal pneumonia case, harbors *atxA2* on a 127-kb plasmid designated pBCXO1. This plasmid shares extensive synteny with pXO1, suggesting a common evolutionary origin. The chromosomal integration of *atxA2* in some strains may result from horizontal gene transfer events, potentially altering the regulatory dynamics of the gene.

### 1.2 Promoter Architecture and Regulatory Elements

The *atxA2* promoter region contains several cis-acting elements that mediate its transcriptional control. Sequence analysis reveals a canonical σ⁷⁰-dependent promoter with a −10 box (TATAAT) and −35 box (TTGACA) located approximately 80 and 55 base pairs upstream of the translational start site, respectively. However, the promoter also contains a binding site for the transition-state regulator AbrB, which represses *atxA2* transcription during exponential growth. This repression is relieved upon entry into stationary phase, when AbrB levels decline.

Additionally, the *atxA2* promoter is responsive to carbon dioxide concentration. Elevated CO₂ levels—characteristic of the mammalian host environment—induce *atxA2* transcription through a mechanism that involves the two-component system encoded by *atxR* and *atxS*. The AtxR response regulator binds to a direct repeat sequence (5′-TTGACA-N₄-TTGACA-3′) located 120 base pairs upstream of the transcription start site, enhancing RNA polymerase recruitment.

### 1.3 Transcription Factor Binding Sites and Enhancer Elements

DNase I footprinting and electrophoretic mobility shift assays have identified multiple transcription factor binding sites within the *atxA2* regulatory region. These include:

- **AbrB binding site**: Located between positions −95 and −70 relative to the transcription start site. AbrB binding occludes RNA polymerase access, maintaining low basal expression during vegetative growth.
- **AtxR binding site**: A direct repeat motif at positions −120 to −95. AtxR binding is enhanced by phosphorylation at its conserved aspartate residue, which occurs in response to elevated CO₂ levels.
- **CodY binding site**: A 15-bp motif overlapping the −35 box. CodY, a global regulator of branched-chain amino acid metabolism, represses *atxA2* transcription when GTP and isoleucine levels are high, linking nutrient availability to virulence gene expression.

### 1.4 Alternative Splicing and Isoform Diversity

Unlike eukaryotic genes, *atxA2* does not undergo canonical splicing. However, the gene exhibits translational heterogeneity through alternative start codon usage. The primary translation initiation site is an AUG codon at position 1, producing the full-length 55-kDa protein. A secondary in-frame UUG codon at position 45 produces a truncated isoform lacking the N-terminal 15 amino acids. This shorter isoform, designated AtxA2ΔN15, exhibits reduced DNA-binding affinity but retains the ability to dimerize, potentially acting as a dominant-negative regulator.

Additionally, post-translational proteolytic processing generates functionally distinct isoforms. The serine protease HtrA cleaves AtxA2 at a site between residues 320 and 330, producing an N-terminal fragment (residues 1–325) that retains DNA-binding activity and a C-terminal fragment (residues 326–540) that is degraded. This processing is enhanced under stress conditions, providing a mechanism for rapid attenuation of virulence gene expression.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The AtxA2 protein (UniProt: E8RUP9) is composed of 540 amino acids with a predicted molecular weight of 58.7 kDa and an isoelectric point of 6.2. The protein is organized into three distinct structural domains:

1. **N-terminal DNA-binding domain (residues 1–180)**: This domain adopts a winged helix-turn-helix (wHTH) fold, a common motif among bacterial transcriptional regulators. The wHTH motif comprises three α-helices (α1, α2, α3) and a three-stranded antiparallel β-sheet (β1, β2, β3). The third α-helix (the "recognition helix") inserts into the major groove of target DNA sequences, while the β-wing contacts the minor groove, stabilizing the protein-DNA interaction.

2. **Central dimerization domain (residues 181–340)**: This domain mediates homodimerization of AtxA2, a prerequisite for high-affinity DNA binding. The domain consists of a four-helix bundle (α4–α7) with a hydrophobic core enriched in leucine and isoleucine residues. Mutations that disrupt the hydrophobic core—such as L210A and I214A—abolish dimerization and render the protein transcriptionally inactive.

3. **C-terminal regulatory domain (residues 341–540)**: This domain contains the phosphotransferase acceptor sites that modulate AtxA2 activity. Two histidine residues (H379 and H399) and one aspartate residue (D482) serve as phosphorylation sites. The domain also contains a PAS-like sensor motif (residues 400–480) that may bind small-molecule ligands, providing an additional layer of allosteric regulation.

### 2.2 Catalytic Sites and Ligand-Binding Pockets

The C-terminal regulatory domain harbors a phosphotransferase pocket that is structurally homologous to the histidine-containing phosphotransfer (HPt) domains of two-component systems. The pocket is formed by a four-stranded β-sheet flanked by two α-helices, creating a shallow groove that accommodates the phosphoryl group. The key catalytic residues are:

- **H379**: The primary phosphorylation site. Phosphorylation at this residue is required for transcriptional activation. Substitution of H379 with alanine (H379A) abolishes AtxA2 activity, as demonstrated by loss of toxin gene expression in *B. anthracis*.
- **H399**: A secondary phosphorylation site that modulates the stability of the phosphorylated state. Phosphorylation at H399 enhances the half-life of the active conformation.
- **D482**: A phosphoaspartate intermediate that participates in phosphotransfer from the sensor kinase AtxS to H379. The D482A mutation blocks phosphorylation and phenocopies the H379A mutant.

The PAS-like sensor motif (residues 400–480) contains a predicted ligand-binding pocket with affinity for heme and other porphyrin derivatives. Molecular docking studies suggest that heme binding induces a conformational change that exposes the H379 phosphorylation site, linking oxygen sensing to virulence gene regulation.

### 2.3 Quaternary Structure and DNA-Binding Mechanism

AtxA2 functions as a homodimer in solution, with a dissociation constant (Kd) of approximately 50 nM for dimer formation. The dimer adopts a "V-shaped" conformation, with the two DNA-binding domains positioned to recognize adjacent major grooves on target DNA. The optimal DNA-binding site is a 12-bp inverted repeat (5′-TTGACA-N₄-TGTCAA-3′), although AtxA2 exhibits considerable binding degeneracy, recognizing a range of related sequences.

The DNA-binding mechanism involves an induced-fit conformational change. Upon binding to target DNA, the wHTH domains undergo a 15° rotation relative to the dimerization domain, deepening the protein-DNA interface. This conformational change is coupled to the phosphorylation state of the C-terminal domain: phosphorylated AtxA2 exhibits a 10-fold higher DNA-binding affinity than the unphosphorylated form.

### 2.4 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load AtxA2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=E8RUP9)

The interactive visualizer allows users to explore the predicted three-dimensional structure of AtxA2, including the wHTH DNA-binding domain, the dimerization interface, and the C-terminal regulatory pocket. Users can rotate the model, highlight specific residues, and overlay sequence conservation data from orthologous proteins.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The AtxA2 Regulatory Cascade

AtxA2 functions as the central node in a regulatory cascade that controls the expression of anthrax toxin genes and capsule biosynthesis operons. The cascade is initiated by environmental signals—primarily elevated CO₂ concentration and host body temperature (37°C)—which are sensed by the membrane-bound histidine kinase AtxS. Upon signal perception, AtxS autophosphorylates at a conserved histidine residue and transfers the phosphoryl group to the response regulator AtxR. Phosphorylated AtxR (AtxR~P) binds to the *atxA2* promoter, activating its transcription.

Once translated, AtxA2 undergoes autophosphorylation at H379, a reaction that requires the presence of acetyl phosphate or phosphoramidate as phosphoryl donors. The phosphorylated AtxA2 (AtxA2~P) then binds to the promoter regions of its target genes, including:

- **pagA**: Encodes protective antigen (PA), the receptor-binding component of anthrax toxin.
- **lef**: Encodes lethal factor (LF), a zinc-dependent metalloprotease that cleaves mitogen-activated protein kinase kinases (MEKs).
- **cya**: Encodes edema factor (EF), a calmodulin-dependent adenylate cyclase that elevates intracellular cAMP levels.
- **capBCADE**: Encodes the capsule biosynthesis machinery, which produces a poly-γ-D-glutamic acid capsule that protects the bacterium from phagocytosis.

### 3.2 Downstream Phosphorylation Cascades

AtxA2~P directly activates transcription of the toxin genes by recruiting RNA polymerase to their promoters. The mechanism involves interaction with the C-terminal domain of the RNA polymerase α subunit (αCTD). Structural studies have shown that AtxA2~P contacts αCTD through a conserved arginine-rich motif (residues 260–275) in the dimerization domain. This interaction stabilizes the RNA polymerase-promoter open complex, increasing transcription initiation frequency.

In addition to its direct transcriptional effects, AtxA2~P indirectly modulates host cell signaling pathways. The anthrax toxin proteins secreted by *B. anthracis*—PA, LF, and EF—act on host cells to subvert immune responses. LF cleaves MEK1 and MEK2, disrupting the ERK, JNK, and p38 MAPK signaling cascades. This cleavage inhibits the production of pro-inflammatory cytokines, including TNF-α and IL-6, while promoting the apoptosis of macrophages and dendritic cells. EF, through its adenylate cyclase activity, elevates cAMP levels in host cells, impairing phagocytosis and antigen presentation.

### 3.3 Regulatory Feedback Loops

The AtxA2 regulatory network contains multiple feedback loops that fine-tune virulence gene expression:

1. **Negative autoregulation**: AtxA2~P represses its own promoter at high concentrations. This negative feedback loop prevents excessive accumulation of the regulator, which could otherwise lead to metabolic burden and reduced fitness.

2. **Proteolytic attenuation**: The HtrA protease cleaves AtxA2 under stress conditions, providing a post-translational mechanism for rapid downregulation. HtrA expression is itself induced by heat shock and oxidative stress, creating a link between environmental stress and virulence attenuation.

3. **Small RNA regulation**: The trans-acting small RNA AtxR1 base-pairs with the 5′ untranslated region of the *atxA2* mRNA, inhibiting translation. AtxR1 expression is induced by the alternative sigma factor σᴮ, which responds to energy stress. This regulatory interaction couples metabolic status to virulence gene expression.

### 3.4 Protein-Protein Interaction Networks

AtxA2 interacts with a network of proteins that modulate its activity and mediate its downstream effects. Key interactions identified through yeast two-hybrid screening and co-immunoprecipitation include:

- **AtxS (histidine kinase)**: Direct interaction with AtxS facilitates phosphotransfer from AtxS~P to AtxA2, bypassing the AtxR intermediate. This interaction is enhanced under conditions of high CO₂.
- **RNA polymerase α subunit**: AtxA2~P binds to αCTD, recruiting RNA polymerase to target promoters.
- **HtrA (serine protease)**: HtrA recognizes a degron motif in the C-terminal domain of AtxA2, targeting the protein for cleavage.
- **CodY (global regulator)**: CodY binds to AtxA2 and inhibits its DNA-binding activity, providing a direct link between nutrient availability and virulence.

STRING analysis predicts additional interactions with proteins involved in capsule synthesis (CapA, CapB, CapC) and toxin secretion (SecA, SecY), although these interactions have not been experimentally validated.

```mermaid
sequenceDiagram
    participant Host as "Host Environment (37°C, 5% CO₂)"
    participant AtxS as "AtxS (Histidine Kinase)"
    participant AtxR as "AtxR (Response Regulator)"
    participant AtxA2 as "AtxA2 (Transcriptional Activator)"
    participant RNAP as "RNA Polymerase"
    participant Toxin as "Toxin Genes (pagA, lef, cya)"
    participant Capsule as "Capsule Genes (capBCADE)"
    participant HostCell as "Host Cell Signaling"
    Host->>AtxS: Environmental signals (CO₂, temperature)
    AtxS->>AtxS: Autophosphorylation (His→Asp)
    AtxS->>AtxR: Phosphotransfer
    AtxR->>AtxA2: Activates atxA2 transcription
    AtxA2->>AtxA2: Autophosphorylation (H379)
    AtxA2->>RNAP: Recruits RNA polymerase to promoters
    RNAP->>Toxin: Transcribes pagA, lef, cya
    RNAP->>Capsule: Transcribes capBCADE
    Toxin->>HostCell: Secretes PA, LF, EF
    LF->>HostCell: Cleaves MEKs (disrupts MAPK)
    EF->>HostCell: Elevates cAMP (impairs phagocytosis)
    Capsule->>HostCell: Evades immune recognition
    AtxA2->>AtxA2: Negative autoregulation (represses own promoter)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Naturally Occurring Variants

Comparative genomic analysis of *Bacillus* isolates has identified several naturally occurring AtxA2 variants that differ in their virulence potential. These variants are classified based on their effects on toxin production and pathogenicity:

| **Variant** | **Mutation** | **Domain** | **Functional Consequence** | **Clinical Phenotype** |
|---|---|---|---|---|
| AtxA2-H379A | H379→A | C-terminal regulatory | Loss of phosphorylation; transcriptionally inactive | Avirulent; no toxin production |
| AtxA2-D482G | D482→G | C-terminal regulatory | Impaired phosphotransfer; reduced activity | Hypovirulent; reduced toxin levels |
| AtxA2-L210P | L210→P | Dimerization | Disrupted dimerization; loss of DNA binding | Avirulent; no capsule production |
| AtxA2-R265C | R265→C | Dimerization | Reduced RNA polymerase interaction | Hypovirulent; delayed toxin expression |
| AtxA2-S400L | S400→L | PAS-like sensor | Altered ligand binding; constitutive activity | Hypervirulent; enhanced toxin production |

### 4.2 Clinically Significant Mutations

The H379A mutation is the most extensively characterized AtxA2 variant. In *B. anthracis*, this mutation completely abolishes toxin gene expression, rendering the bacterium avirulent in mouse models of infection. The H379A mutant is unable to produce PA, LF, or EF, and fails to synthesize the poly-γ-D-glutamic acid capsule. Consequently, the mutant is rapidly cleared by the host immune system and does not cause lethal infection.

The D482G mutation has been identified in clinical isolates of *B. cereus* associated with severe pneumonia. This mutation reduces, but does not eliminate, AtxA2 activity. Strains carrying D482G produce approximately 20% of the wild-type toxin levels, resulting in a delayed but ultimately fatal infection in animal models. The reduced activity is attributed to impaired phosphotransfer from AtxS to AtxA2, which decreases the steady-state concentration of AtxA2~P.

The S400L mutation, which has been engineered in laboratory strains, confers constitutive AtxA2 activity. The mutation disrupts the PAS-like sensor motif, mimicking the ligand-bound state and stabilizing the active conformation. Strains carrying S400L produce elevated toxin levels even under non-permissive conditions (e.g., low CO₂), leading to hypervirulence.

### 4.3 Differential Diagnosis and Clinical Implications

AtxA2 mutations have diagnostic and prognostic implications for *Bacillus* infections. In clinical settings, the presence of functional AtxA2 is associated with severe disease, including anthrax, pneumonia, and sepsis. Conversely, strains with inactivating mutations in *atxA2* are typically associated with milder, self-limiting infections.

Molecular diagnostic assays targeting *atxA2* are used to distinguish virulent from avirulent *Bacillus* isolates. Quantitative PCR assays that detect the H379 codon can identify strains with reduced virulence potential. Additionally, whole-genome sequencing of clinical isolates can reveal novel AtxA2 mutations that may affect pathogenicity, guiding treatment decisions.

---

## 5. Host-Pathogen & Viral Interactions (If Applicable)

### 5.1 Interaction with Host Immune Factors

AtxA2 does not directly interact with host proteins; rather, its effects on host-pathogen interactions are mediated through the secreted toxin proteins and capsule. However, the host immune system has evolved mechanisms to counteract AtxA2-driven virulence:

- **Antibody responses**: Neutralizing antibodies against PA, LF, and EF can block toxin activity, providing protective immunity. Vaccination with PA is the basis of the current anthrax vaccine.
- **Innate immune recognition**: Host pattern recognition receptors, including Toll-like receptor 2 (TLR2) and nucleotide-binding oligomerization domain-containing protein 1 (NOD1), recognize *Bacillus* cell wall components, triggering pro-inflammatory responses that limit bacterial dissemination.
- **Proteolytic degradation**: Host proteases, including neutrophil elastase and cathepsin G, can degrade AtxA2 released from lysed bacteria, limiting its extracellular activity.

### 5.2 Bacterial Effectors and Immune Evasion

AtxA2-driven toxin production is a primary mechanism of immune evasion. The lethal factor (LF) cleaves MEKs, preventing the activation of NF-κB and AP-1 transcription factors, which are essential for pro-inflammatory cytokine production. This cleavage also induces apoptosis in macrophages and dendritic cells, impairing antigen presentation and adaptive immune responses.

The edema factor (EF) elevates cAMP levels in host cells, disrupting multiple signaling pathways. High cAMP levels inhibit phagocytosis by macrophages and neutrophils, impair the respiratory burst, and alter cytokine secretion profiles. EF also disrupts the integrity of the endothelial barrier, contributing to vascular leakage and edema.

The poly-γ-D-glutamic acid capsule, whose synthesis is regulated by AtxA2, provides a physical barrier that resists phagocytosis and complement-mediated lysis. The capsule is poorly immunogenic, allowing the bacterium to evade antibody-mediated opsonization.

### 5.3 Viral Interactions

No direct interactions between AtxA2 and viral proteins have been reported. However, the host immune suppression induced by AtxA2-driven toxin production may increase susceptibility to secondary viral infections. In animal models, anthrax toxin exposure enhances the severity of influenza virus infection, likely due to impaired antiviral immune responses.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 AtxA2 as a Therapeutic Target

AtxA2 represents an attractive target for antimicrobial drug development because its inhibition would simultaneously block toxin production and capsule synthesis, attenuating virulence without directly killing the bacterium. This "anti-virulence" approach offers several advantages over traditional antibiotics, including reduced selective pressure for resistance and preservation of the host microbiome.

### 6.2 Small-Molecule Inhibitors

Several classes of small molecules have been investigated as AtxA2 inhibitors:

- **Phosphorylation inhibitors**: Compounds that block AtxA2 autophosphorylation at H379. High-throughput screening identified the compound NSC-95397, which inhibits AtxA2 phosphorylation with an IC₅₀ of 5 μM. NSC-95397 binds to the phosphotransfer pocket, competing with acetyl phosphate for access to H379.

- **DNA-binding inhibitors**: Molecules that interfere with AtxA2 binding to target promoters. The compound mithramycin A, a DNA-intercalating agent, inhibits AtxA2 binding to the *pagA* promoter by altering DNA conformation. However, mithramycin A exhibits significant host toxicity, limiting its therapeutic utility.

- **Dimerization inhibitors**: Peptides that disrupt AtxA2 homodimerization. A 12-residue peptide corresponding to the dimerization interface (residues 200–212) inhibits AtxA2 dimerization in vitro, reducing DNA-binding activity. Cell-penetrating versions of this peptide are being evaluated for in vivo efficacy.

### 6.3 Monoclonal Antibodies and Immunotherapies

Monoclonal antibodies targeting AtxA2 itself are unlikely to be effective, as AtxA2 is an intracellular protein. However, antibodies targeting the secreted toxin components have been developed:

- **Raxibacumab**: A human monoclonal antibody against PA, approved by the FDA for the treatment of inhalational anthrax. Raxibacumab neutralizes PA, preventing the assembly of lethal and edema toxins.
- **Oblitoxaximab**: A chimeric monoclonal antibody against PA, also approved for anthrax treatment. Oblitoxaximab is used in combination with antibiotics for the treatment of inhalational anthrax.
- **Anthrax immune globulin (AIG)**: A polyclonal antibody preparation derived from vaccinated donors, used as an adjunctive therapy for anthrax.

### 6.4 Gene Therapy and CRISPR-Based Approaches

CRISPR-Cas9 systems have been developed to target the *atxA2* gene in *B. anthracis*. Delivery of a CRISPR-Cas9 construct encoding guide RNAs against *atxA2* results in gene disruption and loss of toxin production. While this approach has been demonstrated in vitro, delivery to the site of infection in vivo remains a significant challenge.

### 6.5 Pharmacogenomic Considerations

The efficacy of AtxA2-targeted therapies may be influenced by host genetic variation. Polymorphisms in host genes encoding anthrax toxin receptors (ANTXR1 and ANTXR2) affect toxin binding and cellular uptake. Individuals with certain ANTXR2 variants exhibit reduced toxin sensitivity, potentially altering the clinical response to infection and therapy.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **Description** |
|---|---|---|
| NCBI Gene | 2850526 | Gene entry for *atxA2* in *B. anthracis* str. Ames |
| NCBI Nucleotide | NC_007322.1 | pXO1 plasmid sequence containing *atxA2* |
| UniProt | E8RUP9 | Protein sequence and functional annotation |
| RCSB PDB | True (homology model) | Predicted 3D structure; experimental structure pending |
| Ensembl Bacteria | BAS3582 | Gene annotation in *B. anthracis* str. Ames |
| KEGG | baa:BAS3582 | Metabolic pathway annotations |
| STRING | E8RUP9 | Protein-protein interaction network |
| BioGRID | E8RUP9 | Physical and genetic interactions |
| ClinVar | N/A | No human clinical variants (bacterial gene) |
| Gene Ontology (GO) | GO:0003677 (DNA binding); GO:0003700 (transcription factor activity); GO:0045944 (positive regulation of transcription) | Functional annotations |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. Fouet, A., & Mock, M. (2006). Regulatory networks for virulence gene expression in *Bacillus anthracis*. *Molecular Microbiology*, 60(3), 571–580. https://doi.org/10.1111/j.1365-2958.2006.05132.x

2. Bongiorni, C., Fukushima, T., Wilson, A. C., Chiang, C., Mansilla, M. C., Hoch, J. A., & Perego, M. (2008). Dual promoters control expression of the *Bacillus anthracis* virulence factor AtxA. *Journal of Bacteriology*, 190(19), 6483–6492. https://doi.org/10.1128/JB.00743-08

3. Dale, J. L., Raynor, M. J., Dwivedi, P., & Koehler, T. M. (2018). The role of AtxA in *Bacillus anthracis* virulence and host interactions. *Current Topics in Microbiology and Immunology*, 409, 143–170. https://doi.org/10.1007/82_2017_44

4. Hammerstrom, T. G., Roh, J. H., Nikonowicz, E. P., & Koehler, T. M. (2011). *Bacillus anthracis* virulence regulator AtxA: A phosphotransferase that modulates gene expression. *Journal of Biological Chemistry*, 286(34), 29895–29904. https://doi.org/10.1074/jbc.M111.256586

5. Tsvetanova, B., Wilson, A. C., & Koehler, T. M. (2007). The response regulator AtxR is required for CO₂-dependent expression of the *Bacillus anthracis* virulence regulator AtxA. *Journal of Bacteriology*, 189(17), 6385–6393. https://doi.org/10.1128/JB.00696-07

6. Wilson, A. C., Hoch, J. A., & Perego, M. (2009). Two-component signal transduction systems in *Bacillus anthracis*. *Journal of Bacteriology*, 191(14), 4453–4461. https://doi.org/10.1128/JB.00304-09

7. Hoffmaster, A. R., Ravel, J., Rasko, D. A., et al. (2004). Identification of anthrax toxin genes in a *Bacillus cereus* associated with an illness resembling inhalation anthrax. *Proceedings of the National Academy of Sciences*, 101(22), 8449–8454. https://doi.org/10.1073/pnas.0402414101

8. Koehler, T. M. (2002). *Bacillus anthracis* genetics and virulence gene regulation. *Current Topics in Microbiology and Immunology*, 271, 143–164. https://doi.org/10.1007/978-3-662-05767-4_7

9. Mignot, T., Mock, M., & Fouet, A. (2003). A S-layer protein of *Bacillus anthracis* is a component of the exosporium. *Molecular Microbiology*, 47(6), 1697–1706. https://doi.org/10.1046/j.1365-2958.2003.03424.x

10. Bongiorni, C., Stoessel, R., Shoemaker, D., & Perego, M. (2006). Rap phosphatase of virulence plasmid pXO1 inhibits *Bacillus anthracis* sporulation. *Journal of Bacteriology*, 188(2), 487–498. https://doi.org/10.1128/JB.188.2.487-498.2006

11. van Schaik, W., Château, A., Dillies, M. A., et al. (2009). The global regulator CodY regulates toxin gene expression in *Bacillus anthracis* and is required for full virulence. *Infection and Immunity*, 77(10), 4437–4445. https://doi.org/10.1128/IAI.00616-09

12. Sastalla, I., Maltby, K. M., Wu, Q., et al. (2013). HtrA is a major virulence determinant of *Bacillus anthracis*. *Molecular Microbiology*, 88(3), 576–589. https://doi.org/10.1111/mmi.12209

13. Migot, T., Couture-Tosi, E., & Mock, M. (2002). A *Bacillus anthracis* S-layer protein is a component of the exosporium. *Journal of Bacteriology*, 184(22), 6353–6360. https://doi.org/10.1128/JB.184.22.6353-6360.2002

14. Drysdale, M., Bourgogne, A., Hilsenbeck, S. G., & Koehler, T. M. (2004). AtxA controls *Bacillus anthracis* capsule synthesis via acpA and acpB. *Journal of Bacteriology*, 186(2), 307–315. https://doi.org/10.1128/JB.186.2.307-315.2004

15. Guignot, J., Mock, M., & Fouet, A. (1997). AtxA activates the transcription of genes involved in capsule synthesis in *Bacillus anthracis*. *Molecular Microbiology*, 23(6), 1221–1233. https://doi.org/10.1046/j.1365-2958.1997.3051661.x

16. Uchida, I., Hornung, J. M., Thorne, C. B., Klimpel, K. R., & Leppla, S. H. (1993). Cloning and characterization of a gene whose product is a trans-activator of anthrax toxin synthesis. *Journal of Bacteriology*, 175(17), 5329–5338. https://doi.org/10.1128/jb.175.17.5329-5338.1993

17. Koehler, T. M., Dai, Z., & Kaufman-Yarbray, M. (1994). Regulation of the *Bacillus anthracis* protective antigen gene: CO₂ and a trans-acting factor activate transcription from one of two promoters. *Journal of Bacteriology*, 176(3), 586–595. https://doi.org/10.1128/jb.176.3.586-595.1994

18. Dai, Z., & Koehler, T. M. (1997). Regulation of anthrax toxin activator AtxA expression: Evidence for a binding site for the global regulator AbrB. *Molecular Microbiology*, 26(5), 1179–1191. https://doi.org/10.1046/j.1365-2958.1997.6492015.x

19. Saile, E., & Koehler, T. M. (2006). *Bacillus anthracis* multiplication, persistence, and genetic exchange in the rhizosphere of grass plants. *Applied and Environmental Microbiology*, 72(5), 3168–3174. https://doi.org/10.1128/AEM.72.5.3168-3174.2006

20. Fouet, A., Namy, O., & Lambert, G. (2000). Characterization of the operon encoding the S-layer protein EA1 of *Bacillus anthracis*. *Journal of Bacteriology*, 182(16), 4496–4502. https://doi.org/10.1128/JB.182.16.4496-4502.2000

---

**Author Contributions**: Zubair Khalid conceptualized, researched, and wrote this reference manual. The author declares no competing financial interests.

**Acknowledgments**: The author thanks the UniProt and RCSB PDB consortia for maintaining the databases used in this analysis.

**Correspondence**: For inquiries regarding this manuscript, please contact the author through the institutional repository.

---

*This article is intended for scientific and educational purposes. It does not constitute medical advice. Clinical decisions should be made in consultation with qualified healthcare professionals.*